Dr. Francis Collins, Director of NIH
This week, Mark and Margaret speak with Dr. Francis Collins, Director of the National Institutes of Health about the broad scope of research underway at NIH as well as his previous work leading the team that mapped the human genome, for which he won the Presidential Medal of Freedom.
( Music )
Mark Masselli: This is Conversations on Health Care. I am Mark Masselli.
Margaret Flinter: And I am Margaret Flinter.
Mark Masselli: Well Margaret , there’s an interesting new poll out there, Americans
response to the Affordable Care Act, it’ s another poll of course. And according to CNN,
54% of the American still have an unfavorable view of the health care law.
Margaret Flinter: Well I saw that and what’s remarkable about that poll, Mark, is that
15% of those who express opposition did so because they felt it didn’t go far enough to
expand health coverage, that’s an interesting spin.
Mark Masselli: Go figure. Well, the law has been in place for three years now and it
doesn’t rule out fully until January 1st, 2014, 43% of those poll s were in favor of the
health care law which is about the same level of favorability from 2010, so not much
change there.
Margaret Flinter: And the poll also shows continuing deep divide among the
generations regarding the health care law while the majority of young American support
the Affordable Care Act that support drugs to 31% among seniors who -- I would argue
we’re going to be affected the least by it.
Mark Masselli: I think they are, but most of them are on Medicare, certainly those over
65. I think poll points to the need from work clear messaging from the Obama
Administration on aspects of the health law that are good for Americans there is a
massive information campaign being launch soon to foster more understanding about
the Affordable Care Act bu t a big needle to move.
Margaret Flinter: And there does seem to be a real need for that kind of campaign, a
recent Kaiser Family Foundation profound that four in 10 Americans don’t even know
the health care law is on the books. The information campaign is set to launch this
summer, will cover all 50 states and multiple media platforms be very interesting to see
how they approach it.
Mark Masselli: I think they need to be direct and clear about the aspects of the
Affordable Care Act and I think people wants to hear, will be less fearful of the unknown
but the drum beat of negative messaging continues on baited in congress if only the
political divisiveness over the law which subside.
Margaret Flinter: Well, it’s a nice law but it doesn’t appear likely , Mark. Just last week
Republicans in the House passed yet another repeal measure on the Affordable Care
Act and like the ones before one survive the senate but it does show how determine the
opponents of the health care law are to see it repealed or to k eep that thought in the
public consciousness.
Mark Masselli: That same political obstructionism is impacting health care on another
front, Margaret. We’re in the third month of the sequester and it’s impacting quite a few
research programs around the co untry. Out guess today has warn that randomly
cutting funding for ongoing health research could have dire consequences.
Margaret Flinter: Dr. Francis Collins is the Director of the National Institutes of Health
and also led the team that mapped the Huma n Genome which is a monumental
achievement that not only created this blueprint for genetics moving forward also yield
120% return on every federal dollar spent on the project, that’s pretty remarkable.
Mark Masselli: That is, and we’ll hear from Lori Ro bertson Managing Editor of
FactCheck.org, always on the hunt for the truth and false. She had spoken about health
policy in this country.
Margaret Flinter: And no matter what the topic, you can hear all of our shows by going
to CHC Radio.
Mark Masselli : And as always, if you have comments, email us at www.chcradio.com or
find us on Facebook or Twitter. We would love to hear from you.
Margaret Flinter: Now we will get to our interview with Dr. Francis Collins in just a
moment.
Mark Masselli: But first, here is our producer Marianne O'Hare with this week’s
Headline News.
( Music )
Marianne O'Hare: I am Marianne O'Hare with these Health Care Headlines. The health
care law continues to draw critics and politic al action from a number of sectors and
maybe yet another attempt to pass legislation to repeal the Affordable Care Act in
congress last week, political action committees are entering the fray to block elements
of the health care law from coming into being. A new anti - ObamaCare Action Group
restore America’s voice and advocacy of -- the Heritage Foundation and the Tea Party’s
Freedom Works have align forces to back the role out of the online health insurance
exchanges. Well, opposition to the health care p rogram is nothing new, the tactics are
changing rather than focusing on repealing the law in Congress and the courts, two
avenues had failed so far, the groups are aiming to prevent the corner stone of the
legislation, the insurance exchanges from succeedi ng, their goal is to limit enrollment ,
drive up cost and make it easier to roll back all or a part of the law later.
Meanwhile the Obama Administration is getting ready to roll out a massive information
campaign to inform the public about the health care law and how it works. The
Department of Health and Human Service has also planning on mobilizing navigators
throughout the country to facilitate informing the public about the health care law and
how to navigate those online exchanges.
Pesticides and Par kinson, another study proving a link between the two, researches at
the San Matteo Foundation in Italy compared results from studies done between 1975
and 2011 charting patient, exposure to pesticide and the occurrence of Parkinson’s
disease and they found that among those with regular exposure, they were 58% more
likely to develop Parkinson’s. The study looked at a variety of pesticides and the risk s
seem greater among those with regular exposure on farms and in industrial growing
settings. Public used p esticides pose less of a risk.
If you’re obese, you’re at risk of discrimination from your medical provider. A study out
of North Carolina found that a third year med students Harvard Bias against overweight
patients and two - thirds of them were unaware o f that bias. The study yet had
responses from med students in Winston - Salem North Carolina but they say it reflects a
wider sub conscious prejudice against patients who are overweight . It could lead to a
poor treatment of those patients as well.
I am Ma rianne O'Hare with these Health Care Headlines.
( Music )
Mark Masselli: We’re speaking today with Dr. Francis Collins, Director of the National
Institute Health which is the world’s largest supporter of biomedical research. Dr.
Collins is a physician - ge neticist who led the human genome project which achieved it’s
goal of mapping the human genome in 2003 and is author of the language of life DNA
and the Revolution of Personalized Medicine. Dr. Collins is an elected member of the
Institute of Medicine and the National Academy of Science . He was awarded the
Presidential Medal of Freedom in 2007 and received the National Medal of Science in
2009. Dr. Collins, welcome to Conversations on Health Care.
Dr. Francis Dr. Francis Collins: It’s a pleasure to be with you, Mark and Margaret.
Mark Masselli: With the National Institute of Health is responsible so much including
thousands of research studies pertaining to medicine and health and the mission of NIH
is that the sick knowledge about the nature and beha vior of living systems and applying
that knowledge enhance health like the life and reduce the burdens of illness. So can
you share with our listeners some of the broader aspects of health in America and what
are the really important health issues that ne ed to be address?
Dr. Francis Collins: Well first let’s point out that we have made a lot of progress when
you look over the last century, the ways in which medical research have taught us about
what are the causes of illness and what we could do about i t, we’ve come a long way.
Human longevity and the United States has been increasing about one year every six
years for the 30 or 40 years and now stands at age 79 and you can look at certain
causes of serious illness or premature death, that are actually diminishing quite
significantly. It happen slowly enough, maybe people don’t notice but heart attack
deaths are down by 60% of where they were 40 years ago, death from stroke down by
70%. HIV/AIDS which used to be a death sentence now associated almost l ike a
normal life span and even cancer which we still have a lot of work to do on is dropping
and each cause of dead about 1% every year which is progress. What are the big
challenges now? Gosh, it’s a very long list but certainly areas of particular nee d and
scientific excitement will include cancer, Alzheimer’s disease, obesity and diabetes, big
threat of course to our nation because of the epidemic, we are encounter here of that
condition and all of it’s consequences. HIV/AIDS we have the chance to ac tually end
that epidemic which is a bold thing to say but I think we could see a path forward to that
or something like autism which is frustrating and growing and it’s frequency and need to
understand it and come up with better intervention. So our plate is very full at the
national institutes of health, we have programs and all of those disorders and many
others trying to find answers.
Margaret Flinter: Dr. Collins, I really appreciate your leading with that good news and
optimism and I do think people don’t realize the progress you’ve made and reducing
dust from heart disease and so many other things as you’ve said, do you personally
have had the opportunity to lead in one of the most transformative breakthroughs at the
modern medical error, the comple te mapping of the human genome took 13 years and
$4 billion which your team did in 2003 and just 10 years later we’ve got the technology
down to where a person could chose to have their entire genome sequence in a day for
maybe a $1000.00. So here we are on the threshold of the ultimate tool for clinicians I
think who seek to provide true personalize medicine. Tell us about the promises and
the challenges and maybe the limitations to genome mix and transforming the way
health care is practice in not too d istant future?
Dr. Francis Collins: Well the genome is the instruction book for human biology, it’s that
wonderful information molecule called DNA with all the letters that make up each of our
instruction books about three billion of them in fact it’s th e human genome and by
having not only sequence that first reference genome but now having a huge amount of
information about differences and how they associate with disease risk and a lot more
about how the genome actually functions. We really are in a po sition to be able to do
some pretty interesting things and one area is the ability to use information about your
DNA along with your family history to predict what you’re at risk for and the future and to
give people a chance to practice more individualize preventive medicine instead of one
size fits all. I think another area where genomic is already having an impact is the
ability to predict for an individual who has a particular disorder where treatment is
needed, what’s the right drug and what’s the rig ht dose for that person? And a lot of
that is determine by differences in DNA and we can measure those in make better
predictions, we called that Pharmacogenomics which is a lot of syllables but I think you
get what that’s about and maybe though the place where genomic is furthest the long in
terms of its impact on health is cancer. Cancer is a disease . The genomic comes
about because of misspellings in the gene somewhere that causes the cells to grow
when they should have stopped. But every cancer is d ifferent, that’s what we’re
learning and so the one size fits all approach to breast cancer or prostate cancer
doesn’t look like it’s the right answer now either if we could actually identify for each
individual, what’s driving their cancer and then pick f rom the list of more targeted drug
therapist, what’s the right mix for that person , w e probably be on the path towards much
better outcomes and less toxicity.
Mark Masselli: Dr. Collins , I really love your simple description of that we have the
instructi on book. What are the challenges and the opportunities and I want to go back
there, is there anything where on the precipice of a revolution in the way that we treat
certain disorders and also is there some concern that once people think we have the
instr uction book that we will get to these answers right away?
Dr. Francis Collins: Well, we do have to be careful and not to over simplify or imply that
answers are immediately at hand, the genome is an incredibly complicated instruction
book and we’re still learning how to read it, we still have way too short of list
interventions available, we have to work very hard and what you’d called translational
science to take the discoveries about what it is that causes cancer and connect those
up. Where there a fe w instances and we all can tell dramatic stories of people who had
far advanced cancer where everything seem to failed and then the cancer got analyze
and they had Achilles heel sort of finding that, oh my gosh, if you just try that drug which
you never wo uld have thought out for that tumor and maybe you’ll get a response and
people suddenly find wow, that tumor is melting away, six months later the person is
back at work. I guess another area where the whole idea of genomics is starting to play
a big role and is to try to figure out what’s going on with children with birth defects or
other kinds of unexplained difficulties in childhood and once in a while you have a
dramatic result, I’ll tell you one about it, there are twins from Texas who had their DNA
s equence to try to find out why this twins were having this progressive neurologic
disease that seem to be threatening to shorten both of their lives fairly dramatically by
the time they were teenagers and what was discovered was a glitch that was
immediate ly clear what was going on, they were missing an enzyme that was necessary
for their bodies to make a particular neurotransmitter that could supplemented actually
in their diet and they’re both now remarkably vibrant and healthy young people which is
th
prett y amazing from a kid who was considered unlikely to make it through her 18
birthday.
Margaret Flinter: You know Dr. Collins you talk about there are being five Ts to medical
research and that influence the technology, talent, threat and telling stories and I think --
-
Dr. Francis Collins: I can tell the story.
Margaret Flinter: You just told the story that will permanently stick with me because it’s
a very compelling story which is why they’re so important.
Dr. Francis Collins: Yes.
Margaret Flin ter: Tell me about the transitions, is this really about how we get the
knowledge of what was accomplish in that specific instance into practice and
disseminated through the health care community, maybe you can talk a little bit about
that and how that wo rks on a policy level at the NIH as well?
Dr. Francis Collins: So translation generally means taking the basic science discoveries
about how life works and how disease occurs which are pouring out of the laboratories
at NIH Supports and making sure that those don’t just sit there but they actually moved
into new ideas about diagnosis and devices and therapeutics and actually provide
benefit to patient in the clinic as quickly as possible, that means trying to identify what
the bottlenecks are and they occ ur all the way along depending on which technology
you’re trying to move forward.
Mark Masselli: We’re speaking today with Dr. Francis Collins, Director of the National
Institute Health which is the world’s largest supporter of Biomedical Research. Dr.
Collins is a physician - geneticist who led the human genome project . He was awarded
the Presidential Medal Freedom and received the National Medal of Science for his
ground breaking work in genomics. Well Dr, Collins, I want to pull the thread a little, t he
conversation you were just having about the value proposition that NIH provides for our
country and look a little behind the scenes at the business paradigm that supports the
research, walk us through a little bit about the struggle that NIH is always f acing but
perhaps now more than ever.
Dr. Francis Collins: Yeah, it is now more than ever and I think we all understand why
that is given the physical stresses, our nation is facing with ballooning deficit and the
need to do something about that. At the same time if you are looking for a way to deck
the economy out of the difficulties that’s in, you probably want to search for investments
that are known that have a return, this is not only the best investment for advancing
human health, it’s also one of the very best investments you can make in the economy.
People have looked at that and come up with some pretty staggering numbers. The
NIH supports directly about 488,000 jobs but when you consider all the way s in which
that supports what goes on in smal l businesses, biotech and pharmaceutical industry,
we’re probably talking more like seven million jobs that are directly related to what NIH
puts their funding into and on top of that it’s clear that every dollar spent on biomedical
research returns more t han two fold in just one year and 85% of our dollars go out to
grants, to our nation’s finest universities and all of the 50 states, so that’s where the
economic benefit occurs. Maybe a one startling example of how to return can occur,
you mention the gen ome project a little bit ago, and that’s something I’m fairly proud of
in terms of how it turned out. But somebody recently look to say just $4 billion that was
spent over 13 years, what have we gotten so far as far as economic return? And they
calculate d like a year ago but it already added up to $796 billion in just the US. So even
accounting for inflation that came to a 141 to one return on investment, it is serious right
now in terms of how those decisions play out particularly in terms of one of tho se five
keys you mentioned which is talent. I’m particularly worried about young scientist or just
getting started who are full of ideas and creativity at a time where science has never
had more potential than right now and yet their chances of getting su pported by NIH are
at historically low levels and could plumb it to almost an imaginably low level which
would make it very difficult for many of those young scientist to keep going.
Margaret Flinter: Dr. Collins, it’s always my sense that one of the not as well known as
it should be treasures of the United States, how the research agenda is set for NIH and
the leadership of NIH in setting the research agenda is important to all of us across the
country, so perhaps you could share a little bit of your tho ughts with us on that.
Dr. Francis Collins: About half of NIH research dollars go into basic science which is
not targeted towards developing a direct advance in medicine and the other half is focus
on translation or in clinical research where they reall y is that intention and our mission in
compass has both of those activities but factored into that is public health needs, so we
pay attention to what are the disorders that are causing the greatest amount of mobility
and mortality and where are the scient ific opportunities to make advances in those
areas and then we try to place our bets in that regard. But we can’t do just that or we
would neglect rare diseases, at the same time by studying rare diseases we often learn
things and the whole thing is actua lly supported by the best peer review system in the
world where any grant that comes to NIH that has to be reviewed by experts, who’ll look
at it and say what’s the promise here, what would happened if this actually work, what’s
the likely if it’s going to work, that is the main reason why NIH has been so successful
over these many decades is that we have absolute rigor in terms of how we decide
where to fund them.
Mark Masselli: Dr. Collins, NIH open up a new division, the National Center for
Advancing T ranslational Science. So it seems to me that you’re doing the -- from the
translational research hopefully to the transformational breakthroughs in primary care
but then back to the transactional work that happens in the day - to - day settings in
primary car e --
Dr. Francis Collins: Yeah.
Mark Masselli: -- or other places, so walk us through that cycle and tell us a little bit
about the impact that you’re having on those hospital and clinic practices.
Dr. Francis Collins: So, sure, the center you mentio ned National Center for Advancing
Translation Science or NCATS is a new arrival on the scene but there are all kinds of
other places along this long complicated failure prone pipeline from an idea to a new
therapy that’s been widely accepted where we aimed to try to knock down barriers. If
you really like to know when you’re contemplating giving a new drug to somebody for a
disease that desperately needs a new treatment is the drug going to be safe and the
way we traditionally have done that has been using small animals and large animals
and hoping they would predict human toxicity but we all know it’s not that reliable.
We’re working with the Department of Defense namely DARPA there, wild and crazy
group of bioengineers, to try to develop biochips loaded up with human cells derived
from this new stem cell technology that allows you to develop those from any individual
representing liver or kidney or heart or brain and to be able to assess in a much more
realistic situation is this drug going to be safe or toxic for that individual? It’s kind of
revolutionized the way we both developed drugs and tested them for safety in the next
five years. This notion that once you have develop something it looks like a good
intervention, you got to be sure it works in t he real world , I’m on the board of the
Patient - Centered Outcomes Research Institute (PCORI) which is new enterprise
supported by the Affordable Care Act which has this main mission trying to develop
research protocols to figure out what really works in the real world and let’s be sure that
we are asking the patients whether they agree and not just checking to see what the
measurements are in the laboratory and that’s going t be I think a major entry into the
space and trying to provide primary care physicia ns with useful information that they
can act upon and be confident and it’s going to apply in their environment.
Margaret Flinter: We’ve been speaking today with Dr. Francis Collins, Director of the
National Institutes of Health, the world’s leading supp ort of biomedical research. Dr.
Collins led the team to first sequence the human genome and as the recipient of the
National Medal of Science. Dr. Collins, thank you so much for joining today on
Conversation on Health Care.
Dr. Francis Collins: It’s be en a pleasure. Thank you.
( Music )
Mark Masselli: At Conversations on Health Care, we want our audience to be truly in
the know when it comes to the facts about health care reform and policy. Lori
Robertson is an award - winning journalist and managing e ditor of FactCheck.org, a non -
partisan, non - profit consumer advocate for voters that aim to reduce the level of
deception in US politics. Lori, what have you got for us this week?
Lori Robertson: Well, Mark and Margaret, we recently looks at claims abou t the
Affordable Care Act from a group called Americans for Tax Reform, the group made the
claim that under the law employers must offer preventive coverage that includes
abortion but that’s not true. The law does require an insurance plans sold on state
based exchanges, cover preventive care but the state is a one that assign what that
preventive coverage is. Some states already have banned abortion coverage beyond
acception for rape (22:14 inaudible) or a danger to the life of the mother and 20 states
h ave banned insurance companies from offering plans that cover abortion on this state
based exchanges. Other states will allow plans to cover voluntary elective abortion but
the law then requires those states to offer one plan on the exchanges that doesn’t cover
abortion. And that’s my fact check for this week. I am Lori Robertson, managing editor
of FactCheck.org.
Margaret Flinter: FactCheck.org is committed to factual accuracy from the country’s
major political players and is a project of the Annenber g Public Policy Center at the
University of Pennsylvania. If you have a fact, that you would like checked, e - mail us at
www.chcradio.com . We will have FactCheck.org’s Lori Robertson check it out for you
here on Co nversations on Health Care.
(Music)
Margaret Flinter: Each week, Conversations highlights a bright idea about how to make
wellness a part of our communities and everyday lives. One in six people in the world
lacks access to drinking water or basic sani tation and statistic show that diarrhea is a
leading cause of death for these populations. In Africa the numbers are staggering with
46% of the residents have sub -- so here in Africa having no direct access to clean
water. In 2005, artist Tracy Hawkins went to Tanzania to see what she could do about
it, clay pot water filtration has been around for several hundred years where simple clay
pots lying in the bottom of silver oxide can remove up to 99% of the impurities from
most water sources but no one had undertaken a dedicated program to produce and
distribute this pots. Tracy founded the Sing'isi Pottery Project and began making the
pots with local artisans in this region of Tanzania, she and her team were able to get a
factory built so that they could increase production. The project has served multiple
communities and continues to expand. Independent researchers have determine the
system to be safe, effective and the best part, the health of entire communities has
been improve significantly once each village resident is provided with a clay filtration
system. The pots are inexpensive to produce, easy to handle and the factory has also
create a jobs for local residents, they had since change the name of the organization to
Safe Water Ceramics of East Africa, a simple easily manufacture solution that improves
access a portable water for community, one that improves health, well - being, and
economic conditions at the same time, now that’s a bright idea.
( Music )
Margaret Flinter: This is Conversations o n Health Care. I am Margaret Flinter.
Mark Masselli: And I am Mark Masselli. Peace and health.
Conversations on Health Care, broadcast from the campus of WESU at Wesleyan
University, streaming live at www.wesufm.or g , and brought to you by the Community
Health Center.